Clinical Trials · NCT04513717
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- NRG Oncology
- Enrollment
- 2,753
- Start date
- Jan 2021
- Locations
- 602 sites, United States, Canada
- Primary endpoint
- Metastasis-free survival (MFS)